Showing results (51-60 of 193) with videos related to
Sort By:
Pageof 20
Journal of Alzheimer'S Disease : JAD|August 1, 2022
The Clinical Use of Alzheimer's Disease Biomarkers in Patients with Mild Cognitive Impairment: A European Alzheimer's Disease Consortium SurveyCamilla Caprioglio, Valentina Garibotto, Frank Jessen, et al.International Journal of Geriatric Psychiatry|December 11, 2024
Assessment of Dementia in Minority Ethnic Groups in Europe: A 14-Year Follow-Up SurveyT Rune Nielsen, Alexandre de Mendonça, Lutz Frölich, et al.International Journal of Geriatric Psychiatry|April 27, 2016
Late-onset major depression is associated with age-related white matter lesions in the brainstemJohannes Schwichtenberg, Mansour Al-Zghloul, Hans U Kerl, et al.Psychiatry Research|July 21, 2004
Concordance of DSM-IV Axis I and II diagnoses by personal and informant's interviewBarbara Schneider, Konrad Maurer, Dieter Sargk, et al.Alzheimer'S Research & Therapy|March 11, 2015
Responder analysis of a randomized comparison of the 13.3 mg/24 h and 9.5 mg/24 h rivastigmine patchJosé L Molinuevo, Lutz Frölich, George T Grossberg, et al.Journal of Alzheimer'S Disease : JAD|August 28, 2019
Multivariate Platelet Analysis Differentiates Between Patients with Alzheimer's Disease and Healthy Controls at First Clinical DiagnosisIsabella Wiest, Tim Wiemers, Max-Joseph Kraus, et al.Occupational and Environmental Medicine|October 18, 2006
Occupational exposure to low frequency magnetic fields and dementia: a case-control studyAndreas Seidler, Petra Geller, Albert Nienhaus, et al.Neuromolecular Medicine|October 27, 2007
Increased T-cell reactivity and elevated levels of CD8+ memory T-cells in Alzheimer's disease-patients and T-cell hyporeactivity in an Alzheimer's disease-mouse model: implications for immunotherapyKatharina Schindowski, Anne Eckert, Jürgen Peters, et al.Neuroscience Letters|December 31, 2013
Hypocretin in cerebrospinal fluid is positively correlated with Tau and pTauMichael Deuschle, Claudia Schilling, F Markus Leweke, et al.Alzheimer Disease and Associated Disorders|June 3, 2009
Safety and tolerability of the rivastigmine patch: results of a 28-week open-label extensionGeorge Grossberg, Carl Sadowsky, Hans Fröstl, et al.Pageof 20